[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336152-105":59,"doc-detail-336152-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-clinicopathological-significance-of-the-cyclin-d1e1-cyclin-dependent-kinase-cdk246-retinoblastoma-rb1prb1-pathway-in-epithelial-ovarian-cancers","The Clinicopathological Significance of the Cyclin D1/E1 - Cyclin-Dependent Kinase (CDK2/4/6) - Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers","","Cyclin-dependent kinases CDK2, CDK4, and CDK6, together with cyclin D1, cyclin E1, and phosphorylated retinoblastoma (pRB1), regulate the G1/S cell-cycle checkpoint and may affect platinum response in ovarian cancer. The study assessed prognostic and predictive value of the CDK2/4/6–cyclin D1/E1–pRB1 axis in clinical epithelial ovarian cancers. Protein expression was measured in 300 tumors and linked with clinicopathological parameters and patient outcomes, while mRNA expression was evaluated in TCGA. Increased nuclear CDK2 and cyclin E1 predicted worse PFS and OS, and nuclear CDK6 predicted poorer OS. Cytoplasmic CDK4, cyclin D1, and cyclin E1 showed predictive and/or prognostic significance, with multivariate analysis identifying nuclear cyclin E1 as an independent poor PFS predictor. Bioinformatics revealed a positive cyclin E1–CDK2 correlation and enrichment of insulin-signaling and release-related genes in cyclin E1–overexpressing tumors, supporting subcellular localization as a key determinant and suggesting CDK2 targeting in cyclin E1–amplified cancers.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-clinicopathological-significance-of-the-cyclin-d1e1-cyclin-dependent-kinase-cdk246-retinoblastoma-rb1prb1-pathway-in-epithelial-ovarian-cancers/336152/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-clinicopathological-significance-of-the-cyclin-d1e1-cyclin-dependent-kinase-cdk246-retinoblastoma-rb1prb1-pathway-in-epithelial-ovarian-cancers/336152.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What biological axis was evaluated in epithelial ovarian cancers?","Question",{"text":112,"@type":113},"The study evaluated the CDK2/4/6–cyclin D1/E1–pRB1 axis, focusing on how these regulators relate to G1/S checkpoint activity and clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were protein and mRNA levels assessed?",{"text":117,"@type":113},"Protein expression for CDK2/4/6, cyclin D1/E1, and RB1/pRB1 was investigated in 300 ovarian cancers, and mRNA expression was evaluated using the publicly available TCGA ovarian dataset.",{"name":119,"@type":110,"acceptedAnswer":120},"Which markers were linked to worse patient survival?",{"text":121,"@type":113},"Increased nuclear CDK2 and nuclear cyclin E1 were associated with poorer progression-free survival and shorter overall survival, and nuclear CDK6 was associated with poor overall survival.",{"name":123,"@type":110,"acceptedAnswer":124},"What therapeutic implication does the study suggest?",{"text":125,"@type":113},"The findings indicate that subcellular localization matters and support considering CDK2 targeting in cyclin E1–amplified ovarian cancers as a rational approach.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336152,1790169614,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Article  \nThe Clinicopathological Significance of the Cyclin  \nD1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers  \nAyat Lashen 1,2, Mashael Algethami 1, Shatha Alqahtani 1, Ahmed Shoqafi 1, Amera Sheha 1, Jennie N. Jeyapalan 1,3, Nigel P. Mongan 1,3,4, Emad A. Rakha 1 and Srinivasan Madhusudan 1,5, *  \nCitation: Lashen, A.; Algethami, M.; Alqahtani, S.; Shoqafi, A.; Sheha, A.; Jeyapalan, J.N.; Mongan, N.P.; Rakha, E.A.; Madhusudan, S. The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers. Int. J. Mol. Sci. 2024, 25, 4060. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25074060  \nAcademic Editor: Giovanni Tossetta  \nReceived: 29 February 2024  \nRevised: 26 March 2024  \nAccepted: 3 April 2024  \nPublished: 5 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Naaz Coker Ovarian Cancer Research Centre, Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK; [mzxal1@exmail.nottingham.ac.uk](mzxal1@exmail.nottingham.ac.uk) (A.L.); [mszma4@exmail.nottingham.ac.uk](mszma4@exmail.nottingham.ac.uk) (M.A.); [mzxsa20@exmail.nottingham.ac.uk](mzxsa20@exmail.nottingham.ac.uk) (S.A.); [msxas29@exmail.nottingham.ac.uk](msxas29@exmail.nottingham.ac.uk) (A.S.); [mzxas14@exmail.nottingham.ac.uk](mzxas14@exmail.nottingham.ac.uk) (A.S.); [plzjnj@exmail.nottingham.ac.uk](plzjnj@exmail.nottingham.ac.uk) (J.N.J.); [svznpm@exmail.nottingham.ac.uk](svznpm@exmail.nottingham.ac.uk) (N.P.M.); [mrzear1@exmail.nottingham.ac.uk](mrzear1@exmail.nottingham.ac.uk) (E.A.R.)  \n2 Department of Pathology, Nottingham University Hospital, City Campus, Nottingham NG5 1PB, UK  \n3 Faculty of Medicine and Health Sciences, Centre for Cancer Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington LE12 5RD, UK  \n4 Department of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA  \n5 Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK  \n* Correspondence: [srinivasan.madhusudan@nottingham.ac.uk](srinivasan.madhusudan@nottingham.ac.uk)  \nAbstract: Cyclin-dependent kinases (CDK2, CDK4, CDK6), cyclin D1, cyclin E1 and phosphorylatedretinoblastoma (pRB1) are key regulators of the G1/S cell cycle checkpoint and may influence platinum response in ovarian cancers. CDK2/4/6 inhibitors are emerging targets in ovarian cancer therapeutics. In the current study, we evaluated the prognostic and predictive significance of the CDK2/4/6–cyclin D1/E1–pRB1 axis in clinical ovarian cancers (OC) . The CDK2/4/6, cyclin D1/E1 and RB1/pRB1 protein expression were investigated in 300 ovarian cancers and correlated with clinicopathological parameters and patient outcomes. CDK2/4/6, cyclin D1/E1 and RB1 mRNA expression were evaluated in the publicly available ovarian TCGA dataset. We observed nuclear and cytoplasmic staining for CDK2/4/6, cyclins D1/E1 and RB1/pRB1 in OCs with varying percentages. Increased nuclear CDK2 and nuclear cyclin E1 expression was linked with poor progression-free survival (PFS) and a shorter overall survival (OS) . Nuclear CDK6 was associated with poor OS. The cytoplasmic expression of CDK4, cyclin D1 and cyclin E1 also has predictive and/or prognostic significance in OCs. In the multivariate analysis, nuclear cyclin E1 was an independent predictor of poor PFS. Tumours with high nuclear cyclin E1/high nuclear CDK2 have a worse PFS and OS. Detailed bioinformatics in the TCGA cohort showed a positive correlation between cyclin E1 and CDK2 . We a","cbCailmkVo9VUHNH","https://ap.wps.com/l/cbCailmkVo9VUHNH","pdf",6429555,17,"English","# Abstract\n# Introduction\n## Cell cycle regulation and the G1/S checkpoint\n# Materials and Methods\n## Clinical cohort assessment and protein expression analysis\n## TCGA dataset mRNA evaluation\n# Results\n## Nuclear and cytoplasmic expression patterns\n## Prognostic and predictive associations (PFS, OS)\n## Multivariate analysis and biomarker combinations\n## Bioinformatics findings and pathway enrichment\n# Discussion\n## Subcellular localization and therapeutic implications\n# Conclusion","[{\"question\":\"What biological axis was evaluated in epithelial ovarian cancers?\",\"answer\":\"The study evaluated the CDK2/4/6–cyclin D1/E1–pRB1 axis, focusing on how these regulators relate to G1/S checkpoint activity and clinical outcomes.\"},{\"question\":\"How were protein and mRNA levels assessed?\",\"answer\":\"Protein expression for CDK2/4/6, cyclin D1/E1, and RB1/pRB1 was investigated in 300 ovarian cancers, and mRNA expression was evaluated using the publicly available TCGA ovarian dataset.\"},{\"question\":\"Which markers were linked to worse patient survival?\",\"answer\":\"Increased nuclear CDK2 and nuclear cyclin E1 were associated with poorer progression-free survival and shorter overall survival, and nuclear CDK6 was associated with poor overall survival.\"},{\"question\":\"What therapeutic implication does the study suggest?\",\"answer\":\"The findings indicate that subcellular localization matters and support considering CDK2 targeting in cyclin E1–amplified ovarian cancers as a rational approach.\"}]","The Clinicopathological Significance of the Cyclin D1/E1 - Cyclin-Dependent Kinase (CDK2/4/6) - Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers | PDF",1790013846,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba2687bccc3c3431c8d86074f1cc3f01.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b2c2b99096840bf962bc2a0a93d5ea5.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79e8e019ff7770c0d7af80fb5d460260.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6baa16d46d5cf363fd315619a646343.webp",980,1385]